Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caelyx, Docetaxel, and Trastuzumab in Metastatic Breast Cancer
NCT00687440Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2005
- Primary completion
- Oct 2008
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
01
Overview
Phase 2, open-label, single-arm trial of pegylated liposomal doxorubicin in breast cancer, sponsored by Merck & Co. Primary endpoints: Number of Participants Who Had a Tumor Response at 12 months and Incidence of Cardiac Toxicity. Started Jul 2005; status: completed.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00687440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00687440.